2-(3-trifluoromethylphenoxy)-5-nitropyridine | 25935-32-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-(3-trifluoromethylphenoxy)-5-nitropyridine
• 英文别名: 5-nitro-2-(3-(trifluoromethyl)phenoxy)pyridine；5-Nitro-2-[3-(trifluoromethyl)phenoxy]pyridine
• CAS: 25935-32-4
• 化学式: C₁₂H₇F₃N₂O₃
• 分子量: 284.194
• InChiKey: GYJJAGTWEVVCTI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  67.9
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  2-(3-trifluoromethylphenoxy)-5-nitropyridine 以 乙醇 为溶剂， 反应 3.0h， 以55.9%的产率得到6-(3-(trifluoromethyl)phenoxy)pyridin-3-amine
  参考文献：
  名称：

  [EN] NOVEL COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA
  [FR] NOUVEAUX COMPOSÉS APPROPRIÉS POUR LE TRAITEMENT DE LA DYSLIPIDÉMIE

  摘要：

  本发明涉及一般式（I）的化合物，它们的互变异构体，立体异构体，药学上可接受的盐和含有它们的药物组合物。本发明还涉及制备一般式（I）化合物和中间体的过程。本发明的化合物可用于治疗高脂血症等与高脂血症相关的疾病。本发明的化合物还具有降低胆固醇的益处。

  公开号：

  WO2022130352A1
• 作为产物：
  描述：

  2-氯-5-硝基吡啶 、 间三氟甲基苯酚 在 caesium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 24.0h， 以40%的产率得到2-(3-trifluoromethylphenoxy)-5-nitropyridine
  参考文献：
  名称：

  [EN] NOVEL COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA
  [FR] NOUVEAUX COMPOSÉS APPROPRIÉS POUR LE TRAITEMENT DE LA DYSLIPIDÉMIE

  摘要：

  本发明涉及一般式（I）的化合物，它们的互变异构体，立体异构体，药学上可接受的盐和含有它们的药物组合物。本发明还涉及制备一般式（I）化合物和中间体的过程。本发明的化合物可用于治疗高脂血症等与高脂血症相关的疾病。本发明的化合物还具有降低胆固醇的益处。

  公开号：

  WO2022130352A1

文献信息

• FUSED HETEROCYCLIC COMPOUND
  申请人：Ishikawa Tomoyasu

  公开号：US20100216788A1

  公开（公告）日：2010-08-26

  The present invention provides a compound represented by the formula: wherein R 1a is a hydrogen atom, R 2a is a C 1-6 alkyl group substituted by a group represented by —NR 6a —CO—(CH 2 ) n —SO 2 — optionally halogenated C 1-4 alkyl wherein n is an integer of 1 to 4, R 6a is a hydrogen atom or a C 1-4 alkyl group, and —(CH 2 ) n — is optionally substituted by C 1-4 alkyl, R 3a is a hydrogen atom or a C 1-6 alkyl group, R 4a is a halogen atom or a C 1-6 alkyl group, R 5a is a halogen atom or a C 1-6 alkyl group, and X a is a hydrogen atom or a halogen atom, or a salt thereof. The compound of the present invention has a superior tyrosine kinase inhibitory action, is highly safe, and is sufficiently satisfactory as a pharmaceutical product.

  本发明提供了一种化合物，其表示为以下式子：其中，R1a是氢原子，R2a是一个C1-6烷基，被一个表示为—NR6a—CO—（CH2）n—SO2—的基团取代，该基团可选地卤代C1-4烷基，其中n是1至4的整数，R6a是氢原子或C1-4烷基，—（CH2）n—可选地被C1-4烷基取代，R3a是氢原子或C1-6烷基，R4a是卤原子或C1-6烷基，R5a是卤原子或C1-6烷基，Xa是氢原子或卤原子，或其盐。本发明的化合物具有卓越的酪氨酸激酶抑制作用，高度安全，并且作为药物产品完全令人满意。
• Kinetics of the reaction of 2-chloro-3-nitro- and 2-chloro-5-nitropyridines with aryloxide ions in methanol
  作者：Ali A. El-Bardan

  DOI：10.1002/(sici)1099-1395(199904)12:4<347::aid-poc134>3.0.co;2-g

  日期：1999.4

  The kinetics of the reaction of 2-chloro-3-nitropyridine (ortho-like) and 2-chloro-5-nitropyridine (para-like) with a series of aryloxide ions were studied in methanol at different temperatures. Plots of Delta H-not equal versus Delta S-not equal for both reactions gave good straight lines with isokinetic temperatures of 168 and 195 degrees C. Good linear relationships were obtained from the plots of log k(2) against sigma degrees values with relatively large negative rho values indicating the formation of Meisenheimer sigma-complex intermediates. Plots of log k(2) against pK(a) values gave good straight lines indicating that the reactions show an appreciable degree of bond formation in the transition state. An addition-elimination mechanism is suggested. Copyright (C) 1999 John Wiley & Sons, Ltd.
• HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY
  申请人：OTSUKA PHARMACEUTICAL CO., LTD.

  公开号：US20210403456A1

  公开（公告）日：2021-12-30

  The present invention provides a novel heterocyclic compound represented by Formula [I] and a salt thereof: wherein the symbols are as defined in the specification, which is useful for treating, preventing and/or diagnosing seizure and the like in disease involving epileptic seizure or convulsive seizure (including multiple drug resistant seizure, refractory seizure, acute symptomatic seizure, febrile seizure and status epilepticus), as well as a medical use therefor.
• [EN] NOVEL COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA<br/>[FR] NOUVEAUX COMPOSÉS APPROPRIÉS POUR LE TRAITEMENT DE LA DYSLIPIDÉMIE
  申请人：CADILA HEALTHCARE LTD

  公开号：WO2022130352A1

  公开（公告）日：2022-06-23

  Present invention relates to compounds of general formula (I), their tautomeric forms, stereoisomers, pharmaceutically acceptable salts and pharmaceutical composition containing them. Invention also relates to process for the preparation of compounds of general formula (I) and intermediates thereof. Compounds of present invention can be useful in treating diseases such as hyperlipidemia and other disorders related to hyperlipidemia. Compounds of present invention also have a beneficial effect on lowering cholesterol.

  本发明涉及一般式（I）的化合物，它们的互变异构体，立体异构体，药学上可接受的盐和含有它们的药物组合物。本发明还涉及制备一般式（I）化合物和中间体的过程。本发明的化合物可用于治疗高脂血症等与高脂血症相关的疾病。本发明的化合物还具有降低胆固醇的益处。